Shane J. Schaffer

Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is a 25-year pharmaceutical industry veteran with experience in pharmaceutical drug development, commercialization, and biotech commercial operations. During his career, he has held positions at Pfizer, Novartis, and Sanofi (including predecessor companies).

Dr. Schaffer has broad functional and therapeutic expertise through the development and commercialization of several billion-dollar brands including the ADHD Franchise of Ritalin® & Focalin®, Lipitor®, Lyrica®, Eligard®, Arixtra®, Hyalgan®, and Avapro®/Avalide®. He has led the strategic brand planning, franchise resource allocation, and managed care & reimbursement strategy for numerous products.

Dr. Schaffer received his Doctor of Pharmacy degree from the University of Kansas. He served as Chief Fellow and completed a Post-Doctoral Pharmaceutical Industry Fellowship at Rutgers University, College of Pharmacy in conjunction with Warner-Lambert/Parke-Davis, now Pfizer.